Testing for early-onset dementia typically involves a combination of cognitive screening, brain imaging, blood work, and sometimes spinal fluid analysis or genetic testing. There is no single test that confirms a diagnosis. Instead, doctors build a case by layering multiple types of evidence while ruling out treatable conditions that can mimic dementia. The process often takes several appointments over weeks or months.
Early-onset dementia refers to dementia diagnosed before age 65. It affects people in their 30s, 40s, 50s, and early 60s, and it often looks different from dementia in older adults. Younger people are much more likely to have unusual forms where the first symptoms are not memory problems at all. Instead, early signs may include difficulties with vision, language, planning, behavior, or personality changes. Recognizing that distinction matters because it affects which tests are most useful and how quickly a diagnosis is reached.
Why Early-Onset Dementia Is Easy to Miss
One of the biggest challenges with early-onset dementia is that neither patients nor doctors expect it. When a 50-year-old starts struggling to find words or making uncharacteristic decisions at work, the first assumptions tend to be stress, depression, or burnout. The specific symptoms depend on the type of dementia involved, and many of them don’t look like the “forgetfulness” people associate with the disease.
In early-onset Alzheimer’s, the most common subtype, the initial problems are often with vision or spatial awareness rather than memory. Frontotemporal dementia, which is more common in younger adults than in older ones, frequently starts with personality shifts, loss of social awareness, or compulsive behavior. Dementia with Lewy bodies can cause hallucinations, fluctuating alertness, and movement symptoms similar to Parkinson’s disease, like stiffness or trembling. Vascular dementia tends to slow thinking speed and impair planning, organizing, and decision-making before memory is noticeably affected.
If you’re noticing cognitive or behavioral changes that feel out of proportion to stress or aging, pushing for formal evaluation is reasonable. A general practitioner can start the process, but a neurologist or memory clinic will typically lead the diagnostic workup.
Cognitive Screening Tests
The first step in most evaluations is an in-office cognitive screening test. These are short, structured assessments that measure memory, attention, language, and spatial thinking. The most widely used is the Mini-Mental State Examination (MMSE), which takes about 5 to 10 minutes. It’s scored out of 30, with 25 or higher considered normal and anything below 24 suggesting possible cognitive impairment.
The Montreal Cognitive Assessment (MoCA) is another common screening tool, generally considered more sensitive to early or mild impairment than the MMSE. Some clinics also use the Self-Administered Gerocognitive Exam (SAGE), which you can complete on your own before an appointment. These screenings are a starting point, not a diagnosis. A normal score doesn’t definitively rule out early dementia, and an abnormal score doesn’t confirm it. They help determine whether deeper testing is warranted.
Full Neuropsychological Evaluation
If a screening test raises concerns, the next step is usually a comprehensive neuropsychological evaluation. This is a much more detailed assessment, often lasting several hours, that maps out how your brain is performing across multiple domains: memory, executive function (planning, organizing, problem-solving), language, attention, processing speed, and visuospatial skills.
The results create a cognitive profile that helps distinguish between types of dementia and separate true cognitive decline from depression or anxiety, which can cause similar symptoms. For younger patients especially, this profile is critical. Because early-onset dementia often affects non-memory domains first, a standard memory-focused screening can miss what a full battery catches. The evaluation also provides a baseline, making it possible to track changes over time.
Blood Tests to Rule Out Treatable Causes
Before diagnosing dementia, doctors need to eliminate conditions that cause reversible cognitive impairment. A significant portion of cognitive symptoms in younger adults turn out to have treatable causes, which is one reason thorough testing matters so much.
Standard blood work typically includes vitamin B12 levels (deficiency causes cognitive problems that can look like dementia), thyroid and thyroid-stimulating hormone levels (both overactive and underactive thyroid can impair thinking), complete blood counts, and tests for kidney, liver, and blood sugar problems. Depending on your history, doctors may also order a toxicology screen, tests for infections known to cause dementia such as HIV and syphilis, and other targeted panels. These results either point toward a fixable cause or narrow the diagnosis toward a neurodegenerative condition.
Brain Imaging: MRI and PET Scans
Imaging gives doctors a direct look at brain structure and function. Most evaluations start with an MRI, which shows the physical shape and volume of brain tissue. Different types of dementia produce characteristic patterns of shrinkage. In Alzheimer’s disease, atrophy typically appears in the hippocampus (the brain’s memory center) and the areas involved in spatial awareness. Frontotemporal dementia shows shrinkage concentrated in the frontal and temporal lobes, which govern personality, behavior, and language. Dementia with Lewy bodies tends to spare the hippocampus while causing more diffuse cortical thinning. Vascular dementia shows white matter damage and evidence of small strokes.
Volumetric analysis, where software measures the precise size of specific brain structures and compares them to healthy age-matched data, can detect subtle atrophy that a radiologist might not catch on visual inspection alone. This is particularly useful in early-onset cases, where the degree of shrinkage may be modest.
PET scans go a step further by measuring brain activity. A glucose-based PET scan shows which brain regions are using less energy than expected. In Alzheimer’s, reduced activity typically appears first in areas at the back of the brain before spreading forward. In frontotemporal dementia, the pattern is reversed, with the front and sides of the brain affected first. These metabolic patterns help confirm a diagnosis when MRI findings are ambiguous. Amyloid PET scans, which detect the protein plaques associated with Alzheimer’s, can also be used to confirm or rule out Alzheimer’s specifically.
Blood-Based Biomarker Tests
A major recent development is the availability of blood tests that detect Alzheimer’s-related proteins. In May 2025, the FDA cleared the first blood test for diagnosing Alzheimer’s disease. It measures the ratio of two proteins, a form of tau and a fragment of amyloid, in a standard blood draw.
In the clinical study that supported its approval, 91.7% of people who tested positive actually had amyloid plaques confirmed by PET scan or spinal fluid testing. Among those who tested negative, 97.3% were truly negative. Those accuracy numbers are high enough to meaningfully change clinical decision-making. Less than 20% of patients received an indeterminate result.
This test is currently approved for adults 55 and older with cognitive symptoms, so it may not be available to all early-onset patients, particularly those in their 30s or 40s. It is also not a standalone diagnostic tool. Doctors use it alongside other evaluations. Still, it represents a less invasive alternative to PET scans and spinal taps for many patients.
Spinal Fluid Analysis
Cerebrospinal fluid (CSF) testing, done through a lumbar puncture, measures proteins directly associated with Alzheimer’s pathology. The key markers are specific forms of tau protein and amyloid beta. The ratios of these proteins in spinal fluid have roughly 90% agreement with amyloid PET scan results, making CSF analysis a reliable alternative when PET imaging is unavailable or when additional confirmation is needed.
A lumbar puncture sounds intimidating, but the procedure itself takes about 20 to 30 minutes. Most people experience mild soreness or a headache afterward that resolves within a day or two. CSF testing is especially useful in younger patients because their age makes the pretest probability of Alzheimer’s lower, and having a direct biochemical marker helps clarify the diagnosis.
Genetic Testing
Genetic testing is relevant for a specific subset of early-onset cases. Familial Alzheimer’s disease, caused by inherited gene mutations, is very rare overall but accounts for a meaningful share of cases that begin in the 30s, 40s, or 50s. The most important gene is PSEN1, which produces a protein called presenilin 1. Mutations in PSEN1 are the most common cause of familial early-onset Alzheimer’s, responsible for up to 70% of those cases. These mutations cause the brain to overproduce a toxic form of amyloid protein.
Genetic testing is typically offered when someone develops dementia symptoms before age 60 and has a strong family history, meaning a parent or sibling with a similar early diagnosis. Two other genes, PSEN2 and APP, are also tested in this context. If you carry one of these mutations, the chance of developing Alzheimer’s approaches 100%, and the information is relevant for family planning and for siblings or children who may want to know their own risk. Genetic counseling before and after testing is standard because the implications are significant.
What the Diagnostic Timeline Looks Like
From the first appointment to a confirmed diagnosis, the process for early-onset dementia frequently takes longer than it does for older adults. Studies have found that younger patients wait an average of one to three years from first symptoms to diagnosis, partly because doctors are less likely to suspect dementia and partly because symptoms often don’t match the stereotypical memory-loss pattern.
A typical sequence starts with a primary care visit where basic screening and blood work are ordered. If those results raise concern or don’t explain the symptoms, you’ll be referred to a neurologist. The neurologist will likely order brain imaging and a neuropsychological evaluation. Depending on results, CSF testing, advanced PET imaging, or genetic testing may follow. Each step takes days to weeks to schedule and complete, so being proactive about follow-up appointments helps keep the process moving.
Getting a clear answer matters not just for treatment planning but for practical reasons: workplace accommodations, legal and financial planning, access to clinical trials, and family support. If your initial doctor dismisses your concerns, seeking a second opinion from a neurologist or a memory disorders clinic is a reasonable next step.